Ligan, Gilmhar B.

HRN: 24-18-63  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/02/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/02/2023
12/06/2023
IVTT
600mg
Q8
Lefort Fracture, MVA
Waiting Final Action 
12/02/2023
CEFUROXIME 750MG (VIAL)
12/02/2023
12/06/2023
IVTT
750mg
Q8
Lefort Fracture; MVA
Waiting Final Action 
12/05/2023
CEFUROXIME 500MG (TAB)
12/05/2023
12/12/2023
ORAL
500mg
BID
Lefort Fracture Type III
Waiting Final Action 
12/11/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/11/2023
12/18/2023
IV
300mg
1 Hour PTOR Then Q8hr
Panfacial Fracture
Waiting Final Action 
12/12/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/12/2023
12/18/2023
IV
300mg
Q8
Post Op Prohylaxis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: